Progression of macular ischemia following intravitreal bevacizumab

Ophthalmic Surgery Lasers and Imaging

Volumn 40, Issue 3, 2009, Pages 316-318

  Jason Sabet Peyman, E ^a   Heussen, Florian M A ^b   Thorne, Jennifer E ^a   Casparis, Heather ^a   Patel, Sayjal J ^a   Do, Diana V ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEFTRIAXONE; TRIAMCINOLONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RETINA ISCHEMIA; RETINA MACULA LUTEA;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; ISCHEMIA; LASER COAGULATION; MACULA LUTEA; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; OPTIC DISK; RETINAL VASCULITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 67149118999     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20090430-17     Document Type: Article

References (9)

1. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155-2162. (Pubitemid 36520312)
2. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006;19:335-344. (Pubitemid 44279356)
3. Adamis AP, Altaweel M, Bressler NM, et al; and Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113:23-28.
4. Cunningham ET Jr, Adamis AP, Altaweel M, et al; and Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
5. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-354. (Pubitemid 44318195)
6. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26:354-356. (Pubitemid 44318196)
7. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006;26:356-357.
8. Margolis R, Lowder CY, Sears JE, Kaiser P. Intravitreal bevacizumab for macular edema due to occlusive vasculitis. Semin Ophthalmology. 2007;22:105-108. (Pubitemid 46918880)
9. Oshima Y, Oshima S, Nambu H, et al. Different effects of angiopoietin-2 in different vascular beds in the eye: new vessels are most sensitive. FASEB J. 2005;19:963-965. (Pubitemid 40827718)